Rapport Therapeutics, Inc.
RAPP
$27.49
$0.371.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.07% | -9.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.66% | 8.81% | |||
| Operating Income | -1.66% | -8.81% | |||
| Income Before Tax | -0.72% | -11.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.72% | -11.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.72% | -11.09% | |||
| EBIT | -1.66% | -8.81% | |||
| EBITDA | -1.66% | -8.86% | |||
| EPS Basic | 5.89% | -10.54% | |||
| Normalized Basic EPS | 5.90% | -10.55% | |||
| EPS Diluted | 5.89% | -10.54% | |||
| Normalized Diluted EPS | 5.90% | -10.55% | |||
| Average Basic Shares Outstanding | 7.02% | 0.50% | |||
| Average Diluted Shares Outstanding | 7.02% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||